Clinical Trials Logo
  1. Home
  2. Pheochromocytoma
  3. NCT04891081
  4. Details
NCT04891081 Clinical Trial

Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease

Pheochromocytoma Clinical Trial

Official title:
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04891081
Other study ID # 0000
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2019
Est. completion date June 9, 2021

Study information
Verified date May 2021
Source University Medical Centre Ljubljana
Contact Mojca Jensterle, MD, PhD
Phone 03861 522 35 64
Email mojca.jensterlesever@kclj.si
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of our study is to compare plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease and possible association with chronic hypoxic stress.

Recruitment information / eligibility
Status Recruiting
Enrollment 50
Est. completion date June 9, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients with congenital heart disease attending regular follow up Exclusion Criteria: - missing main data in medical documentation

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Slovenia Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia Ljubljana

Sponsors (3)
Lead Sponsor Collaborator
University Medical Centre Ljubljana University of Ljubljana, Faculty of Medicine, University Rehabilitation Institute, Republic of Slovenia

Country where clinical trial is conducted

Slovenia, 

Outcome
Type Measure Description Time frame Safety issue
Primary Plasma metanephrine level Level of plasma metanephrine baseline, one point of time in a cross-sectional study
Primary Plasma normetanephrine level Level of plasma normetanephrine baseline, one point of time in a cross-sectional study
Secondary Hypoxemia Length of hypoxemia presence in years baseline, one point of time in a cross-sectional study
See also
  Status Clinical Trial Phase
Recruiting NCT06050057 - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting NCT05636618 - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors Phase 1/Phase 2
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Terminated NCT05948137 - F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Recruiting NCT00669266 - Adrenal Tumors - Pathogenesis and Therapy
Recruiting NCT05069220 - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor Early Phase 1
Recruiting NCT06062082 - Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
Recruiting NCT04573816 - Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Not yet recruiting NCT06045260 - "Receptor Radionuclide Therapy With 177Lu-DOTATOC Phase 2
Completed NCT00001147 - Blood Sampling for Neurochemical and Genetic Testing N/A
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00001229 - Diagnosis and Treatment of Pheochromocytoma N/A
Completed NCT01967576 - Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03206060 - Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma Phase 2
Not yet recruiting NCT04788927 - Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
Enrolling by invitation NCT03474237 - A Prospective Cohort Study for Patients With Adrenal Diseases